GLIA Diagnostics

The Solution

GLIA Diagnostics offers an innovative diagnostic solution for **traumatic brain injury (TBI)**, particularly in the elderly, focusing on **biomarker-based blood tests** to detect brain injury. Their approach utilises novel micro RNA (miRNA) biomarkers married to point-of-care (POC) device that indicate brain damage. These biomarkers can be measured in blood, offering a **non-invasive** and **rapid** way to diagnose TBI, especially in cases of mild TBI or concussion that may not be detectable through traditional imaging like CT or MRI. This solution is crucial for elderly individuals, who are vulnerable to TBI but may present with symptoms that overlap with other age-related conditions, such as dementia or stroke. By using **this POC**, GLIA Diagnostics provides **early detection** of brain injury, which helps guide clinical decisions and improve treatment outcomes. The technology supports **clinical decision-making**, enabling healthcare providers to differentiate between TBI and other cognitive disorders, and facilitates **early intervention** to mitigate long-term effects like cognitive decline. This technology, most importantly can be used during the recovery phase as well to indicate when the patient is 'safe to return' to normal activities.